Impressions from EASD 2018

Caroline Day

Full Text:



EASD Virtual Meeting Site.

54th EASD Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany, 1–5 October 2018. Diabetologia 2018;61(Suppl 1):1–620.

EASD. Programme at a glance – 54th EASD Annual Meeting.

EASD 2018 - Industry programme.

SGLT2 inhibitors. Diabetologia. Special Issue, October 2018;61:65pp.

Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 2018 Oct 4. pii: dc181749 [Epub ahead of print].

Danne T, Cariou B, Banks P, et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: The European inTandem2 Study. Diabetes Care 2018;41: 1981-90. doi:

Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Data from the CANVAS Program. Circulation 2018;138: 1537–50.

Ryan PB, Buse JB, Schuemie MJ, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: a real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab 2018;20: 2585–97.

Hernandez AF, Green JB, Janmohamed S, et al for the Harmony Outcomes Committees and Investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519–29.

Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2018;6:869–69.

Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018 Oct 3. pii: S0140-6736(18)32260-8 [Epub ahead of print].

Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018;61:2461–98. 10.1007/s00125-018-4729-5 and Diabetes Care 2018

Bohula EA, Wiviott SD, McGuire DK, et al, for the CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018;379:1107–17.

Bohula EA, Scirica BM, Inzucchi SE, et al, for the CAMELLIA–TIMI 61 Steering Committee and Investigators. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet 2018 Oct 3. pii: S0140-6736(18) 32328-6 [Epub ahead of print].

The RISE Consortium. Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 2018;41:1717–25.

Xiang AH, Trigo E, Martinez M, et al, for the RISE Consortium. Impact of gastric banding versus metformin on β-cell function in adults with impaired glucose tolerance or mild type 2 diabetes. Diabetes Care 2018 Oct; dc181662.

Tauschmann M, Thabit H, Bally L, et al, on behalf of the APCam11 Consortium. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet 2018;392:1321–9.

Felton A-M, Hall MS. Diabetes – from St Vincent to Glasgow. Have we progressed in 20 years? Br J Diabetes Vasc Dis 2009;9:142–3.

EASD 2018-EUDF launch event. YouTube.

Sanders AM. The Melbourne Declaration on diabetes. Br J Diabetes Vasc Dis 2014;14:35–7.



  • There are currently no refbacks.

The Journal of the Association of British Clinical Diabetologists